NL-OMON54506招募中2 期
Image-guided de-escalation of neoadjuvant chemotherapy in HER2-positive breast cancer: the TRAIN-3 study. - TRAIN-3
BOOG Study Center0 个研究点目标入组 462 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 462
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. Histologically confirmed primary infiltrating breast cancer.
- •2. Stage II or III disease.
- •3. Overexpression and/or amplification of HER2 in an invasive component of the
- •core biopsy.
- •4. Age <:18
- •5. ECOG Group performance status
- •6. LVEF >50% measured by echocardiography, MRI or MUGA
- •7. Known HR-status ( in percentages)
排除标准
- •1. Previous chemotherapy
- •2. Pregnancy or breastfeeding
- •3. Evidence of distant metastases
- •4. Evidence of bilateraal infiltrating breast cancer
- •5. Concurrent anti-cancer treatment or another investigational drug
研究者
相似试验
进行中（未招募）
1 期
Reducing the number chemotherapy cycles based on radiologic tumor response in HER2-positive breast cancer: the TRAIN-3 study (BOOG 2018-01)HER2-positive, stage II/III breast cancerMedDRA version: 20.0 Level: PT Classification code 10006200 Term: Breast cancer stage II System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10006201 Term: Breast cancer stage III System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10075653 Term: HER2 gene amplification System Organ Class: 10018065 - General disorders and administration site conditionsEUCTR2018-003275-35-NLBOOG Study Center462
进行中（未招募）
2 期
Image-guided De-escalation of Neo-adjuvant Chemotherapy in HER2-positive Breast Cancer: the TRAIN-3 StudyBreast CancerNCT03820063Borstkanker Onderzoek Groep462
Unknown
不适用
De-escalation Protocols in Locoregionally Advanced Nasopharyngeal CarcinomaNasopharyngeal CarcinomaNCT04158518Chaosu Hu118
招募中
不适用
Image-guided radiochemotherapy in patients with pancreatic cancer using gold markers placed during endoscopic ultrasound.Patients with (borderline) resectable or locally advanced pancreatic cancer with an indication for radiochemotherapyNL-OMON23455Academic Medical Center Amsterdam50
Unknown
不适用
Volume De-escalation in Neoadjuvant Radiochemotherapy of Rectal CancerToxicityNCT03975452Campus Bio-Medico University52